Zurcher Kantonalbank Zurich Cantonalbank Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 11.1% during the second quarter, Holdings Channel reports. The institutional investor owned 16,734 shares of the biopharmaceutical company’s stock after selling 2,085 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Halozyme Therapeutics were worth $736,000 […]

Related Keywords

Japan ,United States ,Ireland ,Switzerland ,Belgium ,Matthewl Posard ,Nicole Labrosse ,Zurcher Kantonalbank Zurich Cantonalbank ,Morgan Stanley ,Thompson Davis ,Securities Exchange Commission ,Highmark Wealth Management ,Mt Bank Corp ,First Horizon Advisors Inc ,Nasdaq ,Halozyme Therapeutics Inc ,Wells Fargo Company ,Cetera Advisor Networks ,Holdings Channel ,T Bank Corp ,Halozyme Therapeutics ,Get Rating ,Kantonalbank Zurich Cantonalbank ,Horizon Advisors ,Advisor Networks ,Mark Wealth Management ,Director Matthew ,Exchange Commission ,Visit Holdingschannel ,Halozyme Therapeutics Daily ,Nasdaq Halo ,Halo ,Medical ,40637h10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,